Duration of Crohn's Disease & Response to Vedolizumab Entyvio

Patients who’ve been diagnosed with Crohn’s disease (CD) should begin treatment with an anti-TNF agent or vedolizumab as soon as possible. Dr. Edward Loftus explains details of a study which found that patients with CD for 2 years or less are more likely to achieve a complete response to vedolizumab, than patients with longer disease duration. To learn more, visit mayocl.in/2Nz8cIz